Launch and Sales Contribution of Maxacalcitol Intravenous Injection for Dialysis and Lanthanum Carbonate OD Tablets
First written in FY2019-Q1. 2 of 4 entries say "Restated". Latest entry: FY2019.
4 other companies' latest entry also says "Restated".
- FY2019RestatedAnnual report
「Sales were ¥4,328 million, up 23.8% year on year, owing to the contribution from full-year sales of Maxacalcitol Injection for Dialysis, for which production capacity was increased from November 2018 after production began in the previous fiscal year, and sales of Lanthanum Carbonate OD Tablets, launched in August of the same year.」
The contribution of both products to sales is being reconfirmed. The disclosure states that Maxacalcitol Injection for Dialysis contributed for the full year following the increase in production capacity, while Lanthanum Carbonate OD Tablets were launched in August 2018. - FY2019-Q3RestatedAnnual report
「In the pharmaceutical manufacturing and marketing business, sales of Maxacalcitol Injection for Dialysis, launched in January 2018, and Lanthanum Carbonate OD Tablets, launched in September of the same year, made a significant contribution, resulting in net sales of ¥2,967 million, up 19.7% year on year.」
The continued contribution of both launched products to sales in the pharmaceutical manufacturing and marketing business is being reconfirmed. - FY2019-Q2AdvancedAnnual report
「In the pharmaceutical manufacturing and marketing business, sales increased substantially after we began increasing production of Maxacalcitol Injection for Dialysis, launched in January 2018. In addition, because production costs for Lanthanum Carbonate OD Tablets, launched in September of the same year, were higher than initially expected, net sales were ¥2,017 million and the segment loss was ¥251 million.」
For products already launched, the increase in sales resulting from higher production of Maxacalcitol Injection for Dialysis was disclosed, providing greater detail on performance by product. - FY2019-Q1First statedAnnual report
「In the pharmaceutical manufacturing and marketing business, sales of Maxacalcitol Injection for Dialysis, launched in January 2018, and Lanthanum Carbonate OD Tablets, launched in September of the same year, contributed to results」
The launch timing of the 2 products and their contribution to sales in the pharmaceutical manufacturing and marketing business during the current quarter were disclosed.